Information Provided By:
Fly News Breaks for January 2, 2019
PTLA
Jan 2, 2019 | 09:02 EDT
William Blair analyst Matt Phipps believes Monday's FDA approval of Portola Pharmaceuticals' second-generation manufacturing process of Andexxa opens up a blockbuster opportunity for the company. Given the new supply source, Portola is now on track to significantly broaden the launch of Andexxa in 2019, Phipps told investors in a research note on Monday night. He believes "solid execution" on the commercial front will drive Andexxa sales and shareholder value. He sees additional upside from approval of Andexxa in patients requiring emergency surgery and acute major bleeding on additional anticoagulants, such as edoxaban and enoxaparin, creating a blockbuster opportunity. The analyst keeps an Outperform rating on Portola Pharmaceuticals.
News For PTLA From the Last 2 Days
There are no results for your query PTLA